Amneal Pharmaceuticals (AMRX)
(Real Time Quote from BATS)
$5.74 USD
-0.31 (-5.12%)
Updated Apr 25, 2024 11:12 AM ET
3-Hold of 5 3
A Value D Growth D Momentum C VGM
Income Statements
Fiscal Year end for AMNEAL PHARMACEUTICALS, INC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,394 | 2,212 | 2,094 | 1,993 | 1,626 |
Cost Of Goods | 1,573 | 1,428 | 1,325 | 1,364 | 1,273 |
Gross Profit | 821 | 785 | 769 | 628 | 353 |
Selling & Adminstrative & Depr. & Amort Expenses | 616 | 880 | 616 | 537 | 602 |
Income After Depreciation & Amortization | 204 | -95 | 153 | 91 | -249 |
Non-Operating Income | -34 | 5 | 15 | 19 | 197 |
Interest Expense | 211 | 158 | 136 | 146 | 168 |
Pretax Income | -40 | -248 | 31 | -36 | -220 |
Income Taxes | 8 | 7 | 11 | -104 | 383 |
Minority Interest | 35 | -125 | 10 | -22 | -242 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -49 | -255 | 20 | 69 | -604 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -84 | -130 | 11 | 91 | -362 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 442 | 154 | 395 | 335 | 1 |
Depreciation & Amortization (Cash Flow) | 238 | 249 | 243 | 244 | 250 |
Income After Depreciation & Amortization | 204 | -95 | 153 | 91 | -249 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 176.14 | 150.94 | 151.82 | 148.91 | 132.11 |
Diluted EPS Before Non-Recurring Items | 0.55 | 0.60 | 0.71 | 0.52 | 0.27 |
Diluted Net EPS (GAAP) | -0.48 | -0.86 | 0.07 | 0.61 | -2.74 |
Fiscal Year end for AMNEAL PHARMACEUTICALS, INC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 616.98 | 620.04 | 599.05 | 557.54 |
Cost Of Goods | NA | 427.15 | 387.51 | 379.03 | 379.35 |
Gross Profit | NA | 189.83 | 232.53 | 220.02 | 178.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 144.84 | 156.89 | 139.94 | 143.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 44.99 | 75.64 | 80.08 | 34.45 |
Non-Operating Income | NA | -38.11 | -1.78 | 0.43 | 5.44 |
Interest Expense | NA | 59.55 | 50.91 | 50.86 | 49.32 |
Pretax Income | NA | -83.46 | 22.96 | 29.66 | -9.43 |
Income Taxes | NA | 9.88 | -2.08 | -0.02 | 0.67 |
Minority Interest | NA | 5.30 | 15.35 | 17.77 | -3.15 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -93.34 | 25.03 | 29.68 | -10.09 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -98.65 | 9.68 | 11.92 | -6.94 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 243.71 | 159.69 | 154.89 | 152.11 |
Diluted EPS Before Non-Recurring Items | NA | 0.12 | 0.17 | 0.16 | 0.10 |
Diluted Net EPS (GAAP) | NA | -0.57 | 0.06 | 0.08 | -0.05 |